CAV Regimen for R/R AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

CAV Regimen

Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.

DRUG

MEC Regimen

Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5

Trial Locations (1)

215006

RECRUITING

The First Affliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

collaborator

Northern Jiangsu People's Hospital

OTHER

collaborator

Affiliated Hospital of Nantong University

OTHER

collaborator

Suzhou Hospital of Traditional Chinese Medicine

OTHER

collaborator

Jining Medical University

OTHER

collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

YANCHENG NO.1 PEOPLE'S HOSPITAL

UNKNOWN

collaborator

Kaifeng Central Hospital

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT05657639 - CAV Regimen for R/R AML | Biotech Hunter | Biotech Hunter